G-quadruplex forming sequences are particularly enriched in the promoter regions of eukaryotic genes, especially of oncogenes. One of the most well studied G-quadruplex forming sequences is located in the nuclease hypersensitive element (NHE) III 1 of the c-MYC promoter region. The oncoprotein c-MYC regulates a large array of genes which play important roles in growth regulation and metabolism. It is dysregulated in >70% of human cancers. The silencer NHEIII 1 located upstream of the P1 promoter regulates up-to 80% of c-MYC transcription and includes a G-quadruplex structure (Pu27) that is required for promoter inhibition. We have identified, for the first time, a family of seventeen G-quadruplexforming motifs with >90%
Introduction quadruplex using small molecules to inhibit transcription [39] [40] [41] . We have used a synthetic oligonucleotide sequence encoding Pu27 to inhibit leukemic cell growth and have shown that downregulation of c-MYC expression is associated with inhibition of cell proliferation and induced cell death, although no effects were observed on normal hematopoietic cells [42] .
In addition to their role in transcription regulation, G-quadruplex structures have been shown to be involved in DNA replication by slowing or stopping the replication machinery complex progression and in meiosis where G-quadruplexes overlap with DNA double-strand break sites [4] . They also appear to play important roles in regulation of translation through 5'UTR mRNA containing G-quadruplex structures (review in [43, 44] ). However, the function of such sequences is still poorly understood, especially when one considers the disproportionate number of putative G-quadruplex forming sequences in the genome and the number of genes containing such sequences.
We report here the discovery of seventeen putative G-quadruplex-forming DNA sequences homologous to the parent c-MYC Pu27 genomic (Pu27ge) sequence. These sequences are located on different chromosomes throughout the human genome. We have established that each oligonucleotide sequence of the Pu27 family forms a stable G-quadruplex structure, binds in a sequence specific manner to the NHEIII 1 of the c-MYC promoter and inhibits cell growth of leukemia cell lines. This growth inhibition is accompanied by cell cycle arrest at G1 and S phases and correlates with a decrease in c-MYC expression. Finally we explore the possible role of these sequences by determining their presence in the transcriptome. Our data imply that this family of genomic DNA sequences may be involved in physiologic regulation of c-MYC as well as genes containing such sequences in their promoter regions. In the case of c-MYC regulation, we suggest that this may occur by binding of Pu27 present in the 5'UTR-mRNA transcripts to the complementary sequence NHEIII 1 in the c-MYC promoter in a back-loop mechanism and thereby participating in the transcription machinery in a cell and tissue specific manner.
Material and Methods Oligonucleotides
The sequences for Pu27 and 17 homologous oligonucleotides located in different chromosomes were determined using a BLAT search of Pu27 on the human GRch38 genome assembly [UCSC Genome Browser (http://genome.ucsc.edu)]. The oligonucleotides were purchased from Oligos etc. (Wilsonville, OR) ( Table 1 ). The lyophilized oligonucleotides were reconstituted in sterile nuclease free H 2 O (Millipore, MA) at 500μM and stored at -20°C.
Circular Dichroism (CD) spectrometry
Oligonucleotide samples were diluted at 5μM in TM buffer (50mM TRIS-HCl/2.5mM MgCl 2 , pH7.0), denatured and annealed overnight at room temperature (RT). The concentration was verified by measuring the OD at 260nm in a Diode Spectrometer before the CD measurement on a Jasco J-710 spectropolarimeter in a 1cm Quartz cuvette. Spectra were recorded from 220nm to 340nm at 20°C; four spectra were averaged for each reading. Molar extinction coefficients were calculated using the IDT calculator (IDT.com, oligoAnalyser3.1). CD data were normalized to strand concentration and are expressed in Molar ellipticity [θ] (deg x cm 2 x decimole -1 ).
Samples (4,000 cpm) were then mixed with cold oligonucleotide, boiled for ten minutes and allowed to anneal overnight. An equal volume of 2x glycerol dye was added and run on a 15% native acrylamide gel at 250V for 3h. Bands were visualized by exposing a Kodak phosphorimager screen and scanned using a Molecular Imager (Pharos FX Plus, Bio-Rad) then to Kodak film for 12h at -80°C.
Electrophoretic mobility shift assay (EMSA)
PCR product of 134bp covering the NHEIII 1 of the c-MYC promoter (TS), was incubated with 100,000cpm of 32 P-labeled Pu27 or Pu-HS in 20mM HEPES (pH 7.9), 25mM KCl, 2mM
MgCl 2 , 0.1mM EDTA, 0.2mM DTT, 2mM spermidine and 10% glycerol for 15 min at 37°C. For the competition assay, increasing concentrations of "cold" Pu27 oligonucleotide (1nM to 1μM) were added to each labeled oligonucleotide and incubated for an additional 15 min. After incubation, an equal volume of 2x glycerol dye was added. Complexes (50,000cpm) were resolved by electrophoresis on a 5% non-denaturing polyacrylamide gel, and visualized as described above.
Cross-linking experiment
The target sequences (TS) double strand (ds), C-rich and G-rich single strand (ss) (IDT, Coralville IA) covering the c-MYC NHEIII 1 were hybridized with Pu27 or Pu27 containing the cross-linker [3-cyanovinylcarbazole ( CNV K) kindly provided by Dr. Niles A. Pierce] that was incorporated at the position 1 = PuK1 or position 12 = PuK12 of the Pu27 nucleotide sequence (PuK1 and PuK12 were synthetized by IDT). The cross-linking protocol follows the methodology described by Dr. Pierce [45] with some modifications. The target sequences (1.8μM) were mixed or not with Pu27, PuK1 or PuK12 (3μM) in SSC buffer (150mM NaCl, 15mM trisodium citrate, pH7.0) and annealed for 5min at 95°C in heating block. The samples were then cooled- down at RT for 35min in the dark. Half of each sample was then distributed in a round bottom 96 well plate, placed on ice and irradiated with a UV hand lamp at 365nm for 3min. The samples were then analyzed for crosslinking by: (1) . Electrophoresis in denaturing polyacrylamide gel (12% polyacrylamide/8M Urea) using 2.5μl of the samples mixed with 2X glycerol dye before loading on the gel. A 10bp ladder (Invitrogen) was denatured and run in the 1 st well for size reference. At the end of the electrophoresis the gel was stained with SYBR1 Gold (Molecular Probes) and the bands visualized and photographed in Molecular Imager (Pharos FX Plus, Bio-Rad) and (2) . PCR: 1μl of each sample was mixed with primers designed to recognize the 5'-end (Fw) and the 3'-end (Rev) of the 134bp TS (S1 Table) in tubes containing Ready-To-Go PCR beads (GE Healthcare Bio-sciences, Pittsburgh, PA) and run in a one way PCR using one of the primers or in regular PCR with both primers. Electrophoresis using 2% agarose gel was then used to determine the size of the PCR products. Bands were visualized using ethidium bromide and gel photographed with a gel doc (UVP).
Cell culture
Four leukemia cell lines were investigated: U937 (histiocytic, myeloid lymphoma, AML), Molt-4 (acute-T-lymphoblastic leukemia, ALL), HL-60 (acute promyelocytic leukemia, APL) and Raji (Burkitt's lymphoma, BL), all obtained from American Type Culture Collection (ATCC, Manassas, VA). Cell lines were maintained in culture in RPMI-1640/10%FBS/penicillin-streptomycin (all from HyClone, Utah) at 37°C/5%CO 2 in humid atmosphere and were evaluated at exponential growth.
MTT assay
Cells were seeded at 5x10 3 cells/well in 96-well flat bottom plates in the presence of different concentrations of oligonucleotides for 24h up to 5 days as specified in the text. Untreated cells were used as control, and media for blank. Cell proliferation was evaluated by using MTT [3-(4,5-Dimethylthiazol-2-yl) 2,5-diphenyltetrazolium Bromide) Sigma-Aldrich, St Louis, MO] [42] . Data are shown as percent of the untreated control for an average of at least 3 experiments+/-Standard deviation.
Gene and sequences expression by RT-qPCR U937 were cultured at 1x10 6 cells/5ml in the presence of 10μM Pu27-HS compared to untreated for 72h. At this time point cells were collected and divided in 3 tubes to perform FACS analysis, RNA extraction and protein extraction.
For c-MYC or SOX2 expression. Cells for RNA extraction were pelleted, suspended in 5ml TRIzol 1 reagent (Invitrogen™, NY) and stored at -80°C until samples for 3 separate experiments were collected. RNA extraction was performed following manual instruction and concentration measured on NanoDrop 2000 (NanoDrop, DE). The purified RNA (0.1μg/ sample) was used to generate cDNA with the SuperSript 1 VILO cDNA synthesis Kit following the instruction manual. To detect the expression of c-MYC and SOX2 primer pairs were designed (sequences in S1 Table) , 18S and β-Actin were used as reference genes (all primers from Invitrogen™). SYBR1Green PCR Master Mix (Applied Biosystems1, NY) was used for the RTqPCR reaction in ViiA™7 (Applied Biosystems1). Gene expression was calculated using C T value and ΔΔC T [46] and expressed as fold change averaged for 3 distinct experiments. For the expression of the different Pu27-HS. RNA was extracted from 1x10 6 peripheral blood cells from two healthy donors (Innovative Research, Novi MI) and form the 4 Leukemia cell lines previously used in this study as described above. cDNA was generated with 100ng of RNA and evaluated in RTq-PCR. The primers sequences are located in S1 . Equal amounts of protein were run in 4-15% gradient gel (Bio-Rad) for 1h at 70 V, and then transferred to PVDF membrane using an Iblot (Invitrogen™). The membrane was blocked with 5% non-fat dry milk, washed in PBST (PBS/0.05% Tween), hybridized for 1h at RT with anti-c-MYC antibody or anti-Sox2 (both from Santa Cruz Biotechnology, Inc. TX), α-tubulin or β-tubulin (both form Cell Singnaling technology, MA), were used to normalize the protein loading followed by washes in PBST, then incubated 1h at RT with goat anti-mouse antibody. The protein was visualized using femto-chemiluminescence reagent (Thermo Scientific™ Pierce™).
Statistical analysis
All data are expressed as mean +/-standard deviation (SD) between untreated versus treated and assessed using unpaired two-tailed Student T-test and one-way ANOVA. Data were considered significant for p-value < 0.05.
Results

Pu27 family of quadruplex-forming sequences has 18 members
A BLAT sequence similarity search [UCSC Genome Browser (http://genome.ucsc.edu)] with Pu27ge identified 17 homologous sequences (from 88% to 100% homology) localized on different chromosomes (Fig 1A) . Most of the Pu27 homologous sequences (hereafter referred to as Pu27-HS) are located within gene transcription regions including the noncoding region of SOX2 /Pu3+, GRM6 /Pu5-, and NAV2 /Pu11+ or on the noncoding strand of the genes (Pu27/ c-MYC, Pu20-/CDH4) ( Table 1 ). In several cases the Pu27-HS are located at distance varying from 10Kb to 70Kb from the transcription initiation site of the nearest gene (Table 1) . Among the genes containing a Pu27-HS within their transcription regions are genes producing proteins involved in stem cell maintenance such as c-MYC and SOX2 [47] or differentiation TLE4 [48] , in brain development and neuron differentiation/function such as NAV2 [49, 50] , SDK1 [51] , SPTLC2 [52] , CDH4 (R-cadherin) [53] and GRM6 [54] (Table 2) . Notably, these genes products play a role in embryonic development and in cancer [47, 48, 55, 56] .
The low complexity and repetitive pattern of the Pu27-HS suggests the presence of binding sites for transcription factors (TF). In fact, it has been shown that the P0-P1 region of c-MYC contains binding sites for Nucleolin, SP1 [57] [58] [59] [60] and 4 putative binding sites for Myeloid Zinc Finger 1 (MZF1) [61] . Therefore we performed a search for the presence of possible TF binding sites within the Pu27-HS sequences using readily available bio-informatics websites [(http:// alggen.lsi.upc.es/cgi-bin/promov3/promo/promoinit.cgi?dirDB=TF_8.3), (http://www.cbrc.jp/ research/db/TFSEARCH.html)]. Common binding sites for GR-α, TFII-I, RXR-α and MZF1 (with 1 to 4 binding sites) were identified within all members of the Pu27 family. Putative binding sites for STAT4, c-ETS1 and ELK-1 were also found in most of the Pu27-HS, while SP1, IKZF1, GATA1 or P53 were found in 1 or 2 sequences only (Fig 2) . 
All of the Pu27 homologous sequences form G-quadruplex
Although the Pu27-HS are of different lengths, they all contain a common core of four consecutive runs of three to four guanines suggesting the capability to form G-quadruplex structures. Therefore oligonucleotides encoding each Pu27-HS were analyzed by Circular Dichroism spectrometry (CD). All of the Pu27 family members formed an intramolecular parallel Gquadruplex evidenced by the presence of a peak of Molecular Ellipticity (θ) at 260-262nm ( Fig  1B and S1A Fig) . The higher amplitude obtained with Pu5 can be an indicator of the number of G-tetrad stacks as Pu5 contains 7 runs of 3-4 guanines compared to Pu27 (5 runs). However, it could also be due to the formation of "G-wire" structures which may be observed with long sequences. In order to evaluate the presence of secondary structures, Pu27-HS were subjected to an electromobility shift assay (EMSA). Most Pu27-HS displayed no secondary structures (hair pin, duplex or wires) as shown by the presence of unique bands. However, Pu9 demonstrated a faint band of larger molecular weight which may be due to dimer formation (Fig 1C) . The presence of a unique band for Pu5 confirms that the CD amplitude is most likely due to the number of G-tetrad stacks, ruling out the possibility of wire formation.
All Pu27 homologous sequences bind specifically to the NHEIII 1 target sequence
Next we evaluated whether Pu27 binds to its target sequence (TS) in the c-MYC promoter region [37, 62] . The binding target is a double stranded (ds) DNA fragment of 134bp derived from the c-MYC promoter region containing the proximal NHEIII 1 sequence. EMSA experiments show high affinity binding of Pu27 to the TS ( Fig 1D and S1B Fig: lane 2) , that was competed by adding increasing concentrations of unlabeled Pu27. This competition assay shows a dose-dependent displacement of the 32 P-labeled Pu27/target band (Fig 1D lanes 3-6) with 1nM Pu27 being the minimal concentration required to fully compete with 32 P-Pu27. Importantly, other quadruplex-forming oligonucleotides such as KRAS did not compete with Pu27 for binding to the TS (S1C Fig) . These data strongly suggest that Pu27 binds specifically to NHEIII 1 , stabilizing the genomic G-quadruplex structure thus, inhibiting c-MYC transcription.
The gel shift assay was also used to characterize the binding of the Pu27-HS to the NHEIII 1 sequence and demonstrate that all of the Pu27-HS oligonucleotides bind to the TS (Fig 1E and  S1B Fig: lane 2) and were displaced by unlabeled-Pu27 (Fig 1E and S1B Fig: lane 3) . EMSA control with other G-quadruplex sequences such as 32 P-AS1411 [63] or with 32 P-KRAS [10] showed no binding to the TS (S1D Fig). Taken together these data demonstrate the specificity of the Pu27-HS binding to the NHEIII 1 parent sequence and suggest that the binding occurs at the same site of c-MYC promoter region.
Pu27-homologous sequences inhibit leukemic cells proliferation
We have previously shown that Pu27 downregulates c-MYC expression and inhibits the growth of leukemia cell lines [42] . We therefore assessed the ability of the Pu27-HS oligonucleotides to inhibit the growth of four leukemia cell lines at 5μM and 10μM in 5 day cultures using MTT assay. The effect on cell growth was dose and cell line dependent and the four cell lines investigated in this study show significant inhibition of cell proliferation. Overall, the U937 cell line was less sensitive to Pu27-HS < HL-60 < Molt-4 < Raji (Fig 3) . Notably, all the Pu27-HS oligonucleotides restricted leukemia cell growth, in some cases more effectively than Pu27, such as Pu1, Pu2 or Pu3-. Interestingly, the relative sensitivity of each cell line appears to be different for each Pu27 family member. For instance, U937 cells demonstrate only 30% or less inhibition in the presence of Pu1.2, Pu3+, Pu9, Pu17 or Pu20 (Fig 3A) , while HL-60 seems to be less responsive to Pu9 and Pu16 (Fig 3B) and Molt-4 to Pu1.2, Pu17 or Pu20 (Fig 3D) . All Pu27-HS reduce cell growth by 90% and greater for Raji (Fig 3C) . The cell sensitivity to Pu27-HS may depend on (de)regulation (mutation, translocation. . .) of c-MYC or of other genes containing these sequences and on the presence of NHEIII 1 in the promoter region. Furthermore, the degree of sensitivity could relate to the extent to which proliferation of each cell type is dependent on c-MYC overexpression. For all cell lines, the most potent growth inhibiting sequences were Pu27, Pu1, Pu2, Pu3-, Pu5, Pu7, Pu10.1, Pu10.2 and Pu11.
The AML cell line U937 was used to further investigate the effect of the Pu27-HS in cell culture. This cell line overexpresses c-MYC relative to normal peripheral blood mononuclear cells control (Fig 4A and 4B ) most likely due to the trisomy of chromosome 8 [64] but not from translocation therefore c-MYC expression should remain under the control of the NHEIII 1 .
Pu27-HS control c-MYC expression
One possible mechanism by which the Pu27-HS oligonucleotides inhibit leukemic cell proliferation is by downregulating c-MYC expression as previously shown for Pu27 [42] . Therefore, U937 cells were exposed to either of the Pu27-HS at 10μM for 72h and c-MYC transcription was evaluated by RT-qPCR analysis of total RNA. There was a significant downregulation in c-MYC expression in the cells treated with Pu27, as expected, and with five of the Pu27-HS (Pu2, Pu5, Pu9, Pu14 and Pu17) (Fig 5A) , four of Pu27-HS downregulated c-MYC expression less efficiently (Pu1.2, Pu7, Pu10.2, Pu16). However, c-MYC was significantly upregulated in U937 exposed to four of the Pu27-HS: Pu1, Pu3-, Pu3+ and Pu10.1 (Fig 5A) , four Pu27-HS did not affect c-MYC expression at that time point. The difference observed at the transcription level could be due to difference in specificity -as we expect Pu27 will have higher specificity for its target-or difference in regulation (upregulation instead of downregulation) for these particular Pu27-HS (i.e. Pu1, Pu3-,Pu3+ or Pu10.1). Given the fact that all Pu27-HS can bind to the DNA sequence containing Pu27 target and that all sequences induce growth inhibition at 5 days we wanted to verify the effects of the Pu27-HS on c-MYC protein expression using western blotting assay. There was a marked reduction of c-MYC in all treatment groups compared to untreated control even in cells where there was no change or upregulation of c-MYC transcription (Fig 5B and 5C ) suggesting delay or anomalies in the translation.
Pu27 binds to C-rich strand in the NHEIII 1 of c-MYC promoter To further characterize the binding of Pu27 to its target sequence and determine the mechanism by which this binding could alter c-MYC transcription, we took advantage of a UV activated cross-linker to covalently bind the DNA target sequence and the Pu27 encoding oligonucleotide [45] . The cross-linker [3-cyanovinylcarbazole ( CNV K = K)] is a photoactive nucleoside analogue originally described by Yoshimura et.al. [65, 66] , that was incorporated in Pu27 sequence (at the position 1 = PuK1 or position 12 = PuK12). Pu27, PuK1 and PuK12 were hybridized to the target sequence double stranded (TS-ds) previously used in EMSA assay for the binding study, or with the C-rich and G-rich single strands of the same sequence (C-r ss, G-r ss), then exposed to UV light for crosslinking in order to create a covalent bond (CxL). The presence of binding was confirmed by electrophoresis that revealed a second band of higher molecular weight above the migration band of the TS-ds (Fig 6A) and of the C-rich ss TS but not with G-rich ss TS ( Fig 6B) . As expected from the EMSA experiment, a binding band was also observed with Pu27 without CNV K. Since the crosslink with CVN K is stable even at high temperature [66] we were able to verify the binding using one way PCR with primers designed to recognize each strand of the double strand target. Fig 6C shows an agarose gel run with the PCR products, "Fw" is for the primer reading the C-rich strand and "Rev" for the primer reading the G-rich. Smaller products, indicating Pu27 binding on the strand, were present in Agarose gel for the size of PCR product of the crosslinking samples. One way PCR was realized using "Fw" primer to identify the C-rich strand and "Rev" primer to identify the G-rich stand. The binding of Pu27 to the TS was confirmed by the presence of a smaller band in the C-rich strand.
TS-ds/PuK1, TS-ds/PuK12 and even in TS-ds/Pu27 (although with less product most likely due to loss of the binding in the absence of the crosslinker) when PCR was performed with the Fw primers reflecting binding to the C-rich strand. This was confirmed with the PCR products derived from the cross-linking experiment of the single stranded targets (C-rich and G-rich) with PuK1 and PuK12 that show small PCR products only for PuK1 and PuK12 hybridization with the C-rich strand. Taken together these data suggest that the oligonucleotide encoding the G-rich Pu27 binds by Watson-and Crick binding to the C-rich strand which is the transcribed strand of the c-MYC gene. This result also suggests that all the oligonucleotide sequence members of the Pu27-HS bind in this manner as well. In addition, this result raises the possibility that Pu27 and/or the Pu27-HS bind to the 5'UTR mRNA that will have resulted from the transcription initiation at the P0 promoter and therefore containing the target sequence.
Pu27-HS are specific of the nucleotide sequences in the DNA
Since we have demonstrated that the Pu27-HS are able to modulate c-MYC expression by binding to the target sequence in the c-MYC promoter NHEIII 1 , it is conceivable that other genes containing these sequences could be regulated in the same manner. Among the genes containing such sequences, SOX2 is the most likely to be expressed in the hematopoietic progenitor cells present in leukemia cell lines. The SOX2 promoter contains a G-quadruplex forming sequence of the Pu27 family: Pu3+. SOX2 is a transcription factor present in stem cells involved in the maintenance of stem cell self-renewal and is also part of the transcription cocktail along with c-MYC for the generation and maintenance of iPSC. Furthermore, SOX2 and c-MYC are present at the same transcription sites of a large variety of genes [67] . We verified the expression of SOX2 in the 4 leukemia cell lines investigated in this study and in PBMC from 2 healthy donors. The SOX2 gene was indeed expressed in all cells leukemia and normal PBMC (Fig 7A) . Similarly the expression of SOX2 protein was confirmed by western blotting in the four leukemia cell lines and PBMC (Fig 7B) . However, the protein expression was lower in U937, Molt-4 and especially in Raji compared to HL-60 or to the control PBMC and did not correlate with SOX2 gene expression.
We then investigated the expression of SOX2 in U937 cells exposed to Pu27-HS for 3 days in the same conditions described for c-MYC expression. The RT-qPCR data revealed that SOX2 transcription is modulated in the same manner as c-MYC for at least for 9 out of 18 Pu27-HS (Fig 7C) . For Pu3-, Pu10.1 and Pu14 exposed cells there was no effect on SOX2 expression while c-MYC was upregulated or downregulated, and for Pu11 and Pu16 exposed cells there was no effect on c-MYC expression but significant SOX2 upregulation for Pu11 and downregulation for Pu16 (Fig 7C) . Some of the sequences did not affect SOX2 or c-MYC expression such as Pu1.2, Pu9.2, Pu20 and PuX. All together this data suggest that each Pu27-HS provided similar regulation for the genes containing such sequence, however the mechanism of action can be different i.e. Pu27 downregulates while Pu1 or Pu3+ upregulate gene expression. As for c-MYC the gene and protein expression did not always match, we investigated the effect of the Pu27-HS on SOX2 protein expression by western blotting. The SOX2 protein expression was upregulated in all treatments compared to untreated (Fig 7D) suggesting a possible post-transcriptional regulation by some of the Pu27-HS.
Pu27 homologous sequences induce cell cycle arrest in the G1 and S phases
It is likely that the inhibition of cell proliferation observed in the leukemic cells after 5 days of Pu27 treatment is due to the decrease in c-MYC expression. As c-MYC is involved at different levels in regulating cell proliferation we decided to investigate the cell cycle status of the U937 cell line during exposure to Pu27-HS. U937 cells were grown in the presence of 10μM of the Pu27-HS for 3 days, at which time cells were collected and counted in the exclusion dye Trypan blue to evaluate cell growth and viability. As shown in Fig 8A, by day three cell growth was already significantly reduced in U937 exposed to most of the Pu27-HS compared to untreated; however, there was no significant change in cell viability compared to the control untreated (Fig 8A red bars) except for Pu9 exposed cells where a small but consistent increase in cell death was observed.
While c-MYC is expressed at low levels in quiescent cells, it is induced upon cell division and constitutively expressed throughout the cell cycle [68] . c-MYC is involved at different stages of the cell cycle progression. In addition, overexpression of c-MYC has been suggested to shorten the G1- [69] and the S-phases [70] of the cell cycle in doing so increasing cell division rate. We have previously shown that Pu27 induces cell cycle arrest in G1-phase most likely due to c-MYC downregulation. The analysis of the cell cycle status in U937 exposed to the Pu27-HS confirmed our previous observation of G1 arrest for Pu27 (Fig 8B) . In addition to Pu27, cell cycle arrest at the G1-phase was induced by Pu1, Pu1.2, Pu2 and Pu10.2 which would be consistent with c-MYC involvement in the G1/S phase transition [68] suggesting that these Pu27-HS may affect c-MYC and its downstream target in the same manner. In contrast Pu5, Pu9, Pu11, Pu14, Pu17 and Pu20 induced a cell cycle arrest at the S-phase reflecting the role of c-MYC at different check points of the cell cycle. Nevertheless, the accumulation of cells at either G1-or S-phase of the cell cycle will reduce the relative number of dividing cell and eventually result in growth inhibition.
Some of the Pu27 homologous sequences are present in the transcriptome
As shown in Table 1 most of the Pu27 homologous sequences are located within the untranslated region (UTR) of the mRNA for some genes (c-MYC, SOX2.), or in/or near long non-coding RNA, however some sequences are not located in the vicinity of a gene. In an attempt to understand the role of these sequences in cell function, we investigated whether the Pu27-HS are expressed in the transcriptome of normal and leukemic cells. The total RNA was collected from each cell line at optimal growth and converted to cDNA as was the RNA collected form 2 healthy donors' peripheral blood mononuclear cells (PBMC). The transcription level of each of the Pu27-HS was evaluated by RT-qPCR assay using primer pairs designed to encompass each Pu27-HS on the same strand. The threshold cycle (C T ) was considered significant for a number of cycles below 34 for highly expressed and C T values between 34 and 35 for lowly expressed and not detected for C T values above 35. The data show that Pu3+, Pu11 and Pu14 were highly expressed in all four cell lines and PBMC indicating their presence in the untranslated mRNAwhile Pu2, Pu16 and Pu20 were expressed in leukemic cells and less in PBMC (Fig 9A and 9B) . Some of the Pu27-HS transcripts were present in the leukemia cells but not in the PBMC and some were lowly or not expressed in any of the cells investigated within the scope of this study. The difference in expression of the Pu27-HS between healthy donors PBMC and Leukemia cell lines could reveal a role for these sequences in this malignancy. Notably, Pu27 was lowly transcribed in U937 compared to Molt-4, Raji or HL-60 which seems to express the most correlating Pu27 with c-MYC expression for this cell line. As Pu27 is present in the untranslated region (UTR) of the mRNA, the low level of Pu27 expression in U937 could indicate a low level of UTR-mRNA. The fact that the expression of Pu27 in U937 did not correlate with the expression of c-MYC suggests a truncated or absent 5'UTR-mRNA for this cell line and could reflect the role of such RNA in the gene transcription. Furthermore, the fact that these sequences are expressed at relatively high levels will be consistent with their regulatory role in gene expression.
Discussion
The estimated number of G-quadruplex forming motifs has increased with the decoding of the human genome [7, 71] . Thus, it is not surprising that some G-quadruplex-forming sequences may be found in multiple copies, as is the case for the G-quadruplex-forming sequences within telomeres or centromeres of the chromosomes, reflecting the fact that they share the same function. However, G-quadruplex-forming sequences contained in regulatory regions of eukaryotic promoters have generally been thought to be unique. Unexpectedly, our search for localization of Pu27 revealed 17 putative G-quadruplex forming sequences with a high degree of homology to the sequence of NHEIII 1 in the c-MYC promoter. These DNA sequences, homologous to Pu27, are located in different chromosomes and often are positioned in or near gene transcription sites.
The oligonucleotides encoding all the Pu27-HS were confirmed to form G-quadruplex and to bind specifically to the double stranded Pu27 parent sequence in NHEIII 1 of c-MYC promoter. Furthermore, we have previously shown that Pu27 inhibits cell growth and downregulates c-MYC transcription in leukemic cell lines [42] . We show here that all of the Pu27 family members inhibit cell proliferation as much as, and in some cases even more than Pu27 in four different leukemia cell lines presumably through c-MYC downregulation. The fact that all the Pu27-HS share the Pu27 structure and bind in a sequence-specific manner to the c-MYC promoter silencer raises the possibility of a complex regulatory system for c-MYC (and perhaps for the other genes containing such sequences) that may involve intra-chromosomal and interchromosomal interactions. Such interactions have been reported for enhancers localized at sites distant from the gene promoter such as in the β-globin cluster gene [72] and even, on other chromosomes (T-helper2 cytokines genes [73] ). There is evidence supporting long range control (LRC) of c-MYC transcription, as enhancers have been found as far as 335Kb from the c-MYC promoter [74, 75] and binding sites for CTCF (CCCTC-binding factor) [76] and TCF-4 are present within the promoter region [77, 78] . At least one binding site for CTCF is located within the complementary strand (C-rich) containing NHEIII 1 further suggesting a role in LCR for this silencing element. Another possibility is that one or more of these Pu27-HS may be transcribed into a noncoding transcript which will interact specifically with the parent Pu27 target sequence. Such an interaction if it occurs would be expected to stabilize the G-quadruplex structure keeping the transcription in off position and would be sequence and gene specific. In fact, we found that most of the sequences of the Pu27 family are present in the transcriptome. The relative expression of such sequences seems to be proportional to their presence in the UTR of transcribed genes such as SOX2, NAV2 or SPTLC2 and would likely be cell/tissue specific. It is thus possible that in normal cell function the G-quadruplex contained in the newly transcribed mRNA regulates further transcription in a DNA-RNA back-loop binding as it has been demonstrated for c-MYC 5'UTR mRNA [79] . The low representation of Pu27 in the transcriptome of U937 could be a characteristic of this particular cell line and may reflect the lack of control for c-MYC transcription by the G-quadruplex structure present in the 5'UTR-mRNA.
The fact that most of the Pu27-HS are located within gene transcription sites also suggests a potential role in the regulation of these genes analogous to that of Pu27/NHEIII 1 on c-MYC regulation and therefore they may define concordant pathways for gene regulation. This also predicts cell specificity for these sequences. In this work, the comparison of the effect of the different Pu27-HS on the expression of c-MYC and SOX2 revealed that the majority of these Gquadruplex sequences affect both genes expression in the same manner suggesting that this will be true for all the genes containing such sequences. Furthermore, most of the Pu27-HS affect cells similarly as Pu27 suggesting that they are interchangeable, and confirmed the binding of the Pu27-HS to the same sequences in the gene promoters. This will be in concordance with different regulatory mechanisms utilized by the Pu27-HS depending most likely on the binding site (in the gene or 5'UTR-mRNA) and the cell type/condition (see further for possible mechanisms in Fig 10) . It is however interesting to note that while Pu27 downregulated c-MYC and SOX2 expression (silencing these genes) Pu3+ -which is located in the SOX2 transcribed region-upregulated these two genes expression suggesting different mechanisms of action for Pu27 and Pu3+ to control their respective gene expression at least in this leukemic cell line. It is possible that the difference in gene regulation for Pu27 and Pu3+ depend on the position of their genomic counterpart within their respective gene. Notably, U937 cells were not very sensitive to Pu3+ at day 5 (Fig 2) , however by day 6 about 80% growth inhibition was reached (FR observations). We have also observed a significant down-regulation of SOX2 gene expression in U937 exposed to Pu3+ when cultured at higher density (FR observations). These observations suggest that SOX2 is under a more complex regulatory network most likely dependent on the cell number. It has been suggested that small increase in SOX2 protein can trigger differentiation in mouse embryonic cells [80] it is therefore possible that the increase in expression obtained after Pu27-HS exposure could orient the U937 cells towards differentiation. While we have demonstrated that Pu27 binds to the silencer in c-MYC promoter little is known about Gquadruplex involved in the regulation of SOX2 transcription. Further investigation of G-quadruplex induced regulation of such a key gene as SOX2 would be of the extreme importance for the understanding of cancer and neural development. In addition, the evaluation of the effect each Pu27-HS for the regulation of their respective genes will be informative of the specific role played by these particular G-quadruplex sequences in the cell biology and will likely provide additional possibilities for applications in cancer and stem cell therapy.
We demonstrate in this study that the inhibition of cell proliferation of the U937 cell line by the Pu27-HS was associated with cell cycle arrest at the G1 and S phases suggesting an effect at different regulatory points of the cell cycle. c-MYC is a transcription factor that functions as a transcription regulator for genes in the G1 to S phase transition (E2F1, CDK1. . .), for genes involved in DNA replication and in the check points (CHK1, CHK2, GADD45. . .) thus interfering with the cell cycle progression at different level [81] . Notably, it has been shown that c-MYC accelerates the cell entry into G1 phase, the G1 to S transition and the S-phase progression [68] [69] [70] . Therefore, a decrease in c-MYC expression would explain the cell cycle arrest where cells will not complete mitosis resulting in inhibition in cell proliferation as observed in cells exposed to Pu27 homologous sequence for 5 days.
Although the exact mechanism by which Pu27 inhibits c-MYC expression is not known, it is likely mediated through direct interaction of the oligonucleotide sequence with its genomic counterpart in c-MYC promoter region, either by intermolecular quadruplex formation or by strand invasion [82] . Our in vitro experiments in which Pu27 (G-rich) was covalently crosslinked to its target sequence clearly indicates that the sequence-specific binding occurs with the C-rich strand of the NHEIII1, via strand invasion. Since Watson-Crick binding of the Pu27 oligonucleotide to the C-rich genomic target would inherently stabilize the G-quadruplex structure of the endogenous Pu27 sequence, the transcription machinery would be repressed (1 in Fig 10) . This is very likely the mechanism by which Pu27 oligonucleotide sequences inhibit c-MYC expression. The high sequence similarity of the Pu27-HS suggests that they will preferably bind to the C-rich strand as well. We confirmed that most of the Pu27 family members significantly reduced c-MYC protein expression in leukemic cells. However, this effect was not always the result of a downregulation of c-MYC transcription. Indeed, in some cases the protein expression was reduced even when there was no effect on the c-MYC transcription. This discrepancy could either be result of errors in the transcription of the new mRNA due to the binding of the oligonucleotide sequences to their target NHEIII 1 in Triplex manner (2 in Fig  10) , or of the binding of the oligonucleotides sequences to the 5'UTR-mRNA (3 in Fig 10) as antisense, resulting in both cases in decrease in the translation [83] . At this stage of our investigation, we cannot exclude the possible binding of the exogenous sequences to the G-rich strand of the NHEIII 1 in vivo to form intermolecular G-quadruplex, stabilizing the G-quadruplex to silence transcription (4 in Fig 10) [9] . More studies will be necessary to extensively investigate the actual binding of these sequences in vivo in order to determine exactly how they work. Nevertheless, at this point of our knowledge and with the evidences presented in this study we have proposed a summary of possible mechanisms for Pu27/Pu27-HS inhibition of c-MYC expression in Fig 10. It is interesting to speculate about the reason for the existence of these G-quadruplex motifs which contain a similar core of oligonucleotides sequence but are located in different chromosomes. It is possible that quadruplex-forming sequences represent a generalized mechanical feature as suggested by Sen et al. [1, 84] to stabilize the pairing of homologous chromosomes during meiosis or a common mechanism (protein binding, RNA binding. . .) to regulate transcription of highly expressed genes such as c-MYC. The presence of binding sites for different transcription factors common to all the Pu27-HS is in concordance with shared regulatory mechanism. For instance, the presence of MZF1 binding site(s) in all the Pu27 homologous sequences [61] favors a common mechanism especially in regards to the fact that this transcription factor is involved in differentiation of hematopoietic cells [85] . MZF1 may be involved in an early stage of hematopoiesis and plays a role in terminal differentiation-especially of granulocyte lineage [85] , it has also been shown to regulate c-MYC expression in lung adenocarcinoma [61] . Furthermore, NHEIII 1 requirement for c-MYC transcription silencing is dependent upon formation of Gquadruplex structures [9, 40, 86] . This 3D folding of the segment of DNA will mask the binding of the TF sites thereby impeding c-MYC transcription. In leukemia, c-MYC overexpression may be caused by translocation or amplification implying that the control normally exerted by NHEIII 1 through stable G-quadruplex structure is abolished, thereby freeing TF binding sites that could promote c-MYC expression. The addition of exogenous Pu27 that bind specifically to NHEIII 1 could stabilize the G-quadruplex either by strand invasion of the complementary C-rich strand (as suggested by the crosslinking experiment describe herein) or by Hoogsteen hydrogen bonds on the G-rich strand [82] occupying MZF1 and/or other TF(s) binding sites to restore the regulatory potential of NHEIII 1 .
Nevertheless, the finding of these almost identical nucleotide sequences located in the promoter region of genes involved in stem cell maintenance such as c-MYC and SOX2, neural cell differentiation (SOX2, NAV2, GRM6) or near gene involved in senescence such as BRD7 suggested a shared regulatory mechanism involving sequence specific interactions of either genomic DNA sequences or transcripts of G-quadruplex-forming sequences. Regardless, we believe that the growth inhibitory effects of the Pu27 family of oligonucleotides may provide an opportunity to effectively target c-MYC expression that could be exploited for cancer therapy.
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